BioPharma
M&A Revival In The Biopharmaceutical Sector Back On Track
It is worth noting that the biopharmaceutical sector has gone on to experience a revival when it comes to mergers and acquisitions in the second half of 2023. One can see three major reasons resulting in this uptick in...
BioPharma
Biopharma & Healthcare In Asia-Pacific – Leveraging Ties
In the last five years, there have been various local governments in the Asia-Pacific region that have enacted beneficial policies and also regulatory frameworks to push healthcare and expedite drug development in their respective markets. These initiatives have contributed...
BioPharma
CDMO-Biotech Collab Diminish Business Risk In Drug Creation
Biotech companies go on to face numerous challenges, particularly while in the clinical phase of drug development, in today's fast-paced industry. The astronomically high costs, complicated manufacturing processes, as well as regulatory hurdles related to biologics can go on...
BioPharma
Cryoport, CGT Catapult Partner on Cell and Gene Therapies
Cryoport, Inc. , a leading global provider of innovative products and services to the fast-growing cell and gene therapy industry enabling the future of medicine for a new era of life sciences, and the Cell and Gene Therapy Catapult,...
BioPharma
Biopharma Enhancing Visibility in Connected Supply Chain
The biopharmaceutical industry, with a market value exceeding $350 billion, stands as a cornerstone of global health innovation. The emergence of the Covid-19 pandemic underscored the industry's significance and the necessity for transparent, adaptable, and interconnected supply chains. This...
BioPharma
Cell And Gene Therapy Market Soars, Forecasted At $82.24B
The global cell and gene therapy market has witnessed remarkable growth, with a market size of USD 15.46 billion in 2022. Projections indicate that by 2032, it could reach approximately USD 82.24 billion, showcasing a robust compound annual growth...
BioPharma
Biotech Innovations In The Face of Economic Uncertainty
While the pharmaceutical industry has traditionally been seen as recession-proof, with a constant demand for medicines and new treatment options, it currently faces significant challenges. Economic uncertainty is on the rise, increasing the risks associated with early drug discovery,...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.